BIOLOGICAL TREATMENT OF SEVERE ASTHMA: A COMPARATIVE ANALYSIS OF TEZEPELUMAB, MEPOLIZUMAB, BENRALIZUMAB, AND DUPILUMAB
Authors:
- Agnieszka FilareckaAFAgnieszka Filarecka
- Piotr PrzybyszewskiPPPiotr Przybyszewski
- Emilia PrzybyszewskaEPEmilia Przybyszewska
- Julia GatniejewskaJGJulia Gatniejewska
- Martyna SienickaMSMartyna Sienicka
- Paulina PrudzicPPPaulina Prudzic
- Weronika WiniarskaWWWeronika Winiarska
- Wiktoria Bełcikowska-SkowronWBWiktoria Bełcikowska-Skowron
- Aleksandra SiegmundASAleksandra Siegmund
- Marzena ChrapczyńskaMCMarzena Chrapczyńska
Open Access
- 31 August 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Abstract
Introduction: Bronchial asthma remains a significant clinical problem despite advances in pharmacological treatment. Approximately 5–10% of asthma patients suffer from a severe, uncontrolled form of the disease associated with frequent exacerbations, impaired lung function, reduced quality of life, and increased hospitalization rates. The introduction of biologic therapies targeting Th2-dependent inflammatory pathways has significantly improved treatment outcomes in this group of patients. Aim of the Study: The aim of this study was to analyze and compare the efficacy and safety of biologic therapies used in the treatment of severe asthma, with particular emphasis on tezepelumab, mepolizumab, benralizumab, and dupilumab, based on clinical trials and real-world studies. Materials and Methods: A literature review was conducted using the PubMed database. Original clinical trials, prospective studies, and real-world observational studies published between 2020 and 2026 were included in the analysis. The effects of biologic therapies on asthma exacerbation reduction, improvement in lung function, reduction in oral corticosteroid use, achievement of clinical remission, and long-term treatment safety were evaluated. Results: All analyzed biologic therapies demonstrated significant clinical efficacy in the treatment of severe asthma. Tezepelumab led to a substantial reduction in the number of exacerbations, improvement in pulmonary function parameters, and reduction in oral corticosteroid use regardless of eosinophil levels. Mepolizumab and benralizumab showed comparable efficacy, particularly in patients with eosinophilic asthma. Dupilumab demonstrated high efficacy in patients with type 2 inflammation, especially regarding improvement in lung function. Real-world studies confirmed the effectiveness and favorable safety profile of biologic therapies observed in randomized clinical trials. Conclusions: Biologic therapies constitute an effective and safe treatment option for severe asthma and significantly improve disease control and patients’ quality of life. The strongest clinical evidence concerns tezepelumab, mepolizumab, benralizumab, and dupilumab; however, treatment efficacy may depend on the disease phenotype and inflammatory biomarkers. Further studies are needed to optimize the personalization of biologic therapies and to standardize remission criteria in severe asthma.Keywords
This publication has 29 references indexed in Scilit:
- Biologic Therapies in Severe Asthma: Current Landscape, Clinical Evidence, and Future DirectionsCurrent Pediatrics Reports, 2025
- Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trialThe Lancet Respiratory Medicine, 2025
- Short-term therapeutic effectiveness of tezepelumab in patients with severe asthma: A real-world studyInternational Immunopharmacology, 2025
- Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trialThe Lancet Respiratory Medicine, 2024
- Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M StudyThe Journal of Allergy and Clinical Immunology: In Practice, 2024
- MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and MepolizumabThe Journal of Allergy and Clinical Immunology: In Practice, 2024
- Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR StudyAdvances in Therapy, 2023
- Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysisJournal of Allergy and Clinical Immunology, 2022
- Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 YearsThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAYAnnals of Allergy, Asthma & Immunology, 2021